English

More about this topic

Business

European Commission fines MS drug maker Teva over improper patent use

The European Commission says it has fined the Israeli generic drug maker, Teva, more than €460m for improperly seeking to protect the patent for its multiple sclerosis drug and for disparaging a rival company's development of a competing medicine.

Business

Doliprane-maker Sanofi confirms exclusive talks with US firm CD&R

The American private equity firm has agreed to French government demands about protecting jobs and investment in France.

Business

Sanofi unit bid: Group raises offer, pledging to save French jobs

The proposal from PAI Partners, challenging a US bidder, is the latest twist in a battle to win a 50% stake in Opella, the maker of France's best-selling drug.

Healthcare

Surging drug costs straining national budgets, health insurers warn

Rising pharmaceutical prices, particularly for novel therapies and cancer treatments, are driving increased health spending across Europe, placing significant strain on national budgets, according to a new study published this week.

ADVERTISEMENT

Business

French minister says block to Sanofi deal is still 'on the table'

The potential sale of Opella, which produces Doliprane painkillers, is causing a headache in France.

Business

US private equity firm set to win Sanofi's consumer health division

The proposed offer from Clayton, Dubilier & Rice (CD&R) would mean the sale of a 50% stake in Opella, which makes over-the-counter medicine such as Doliprane and Allegra.

Business

GSK shares leap after drug firm settles US Zantac cancer claim lawsuit

GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies were not reliable.

Business

Weight loss market: Eli Lilly and Novo Nordisk's rivals muscle in

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up to release their own treatments, aiming to challenge the two industry leaders.

Business

Bavarian Nordic shares rise on stronger earnings and major Mpox order

The company recently received a 440,000 smallpox and Mpox vaccine dose contract from an unnamed European country.

Business

Possible drug shortages in Germany as China tightens espionage laws

Several German states have suspended trips by their quality-control inspectors to Chinese pharmaceutical companies over tightened espionage laws.

Business

Vaccine makers see share prices spike as concerns grow over Mpox

The share prices of a number of healthcare and pharmaceutical companies worldwide rose on Friday as the World Health Organisation (WHO) declared a rapidly-spreading African Mpox outbreak a public health emergency.

Markets

Bayer stock soars as German pharma company wins Roundup legal battle

Shares in German pharmaceutical and biotechnology company Bayer climbed nearly 13% on Friday after the company won a legal battle in the US related to its Roundup weedkiller.

Business

AstraZeneca leads in valuation as it bets on cancer drugs portfolio

The company has tied up with Eccogene, a Chinese biotech firm, for a new experimental weight loss drug. The weight loss market is currently dominated by Eli Lilly and Novo Nordisk.

Business

French-born boss of AstraZeneca named highest-paid CEO in Britain

Pascal Soriot headed a list of top earners compiled by the High Pay Centre, with bosses of Rolls Royce and HSBC also included in the top 10.

Business

Novo Nordisk: Earnings trimmed as rivals seek to enter market

Novo Nordisk missed earnings expectations in the second quarter due to growing competition and increased costs from capacity expansions. The company also downgraded its profit outlook for 2024.

Business

Bayer reaps benefits of demand for new cancer and kidney medicines

German pharmaceutical giant Bayer AG released its second quarter and half year 2024 earnings on Tuesday morning, with the company seeing an average performance in the second quarter, due to the agricultural market environment becoming tougher.

Business

Roche plans speedy weight-loss drug launch to catch up with rivals

Roche believes its anti-obesity drugs could have advantages over other more established rivals such as Eli Lilly and Novo Nordisk through ease of scalability that will allow it to meet increased demand.

Business

French pharma giant Sanofi ups profit forecast as Dupixent sales soar

The French pharmaceutical firm announces double-digit sales growth in the second quarter thanks to Dupixent and new products.

Business

AstraZeneca tops second-quarter earnings forecasts and raises guidance

AstraZeneca exceeded market expectations in its second-quarter earnings report. The British pharmaceutical firm has also upgraded its guidance for fiscal year 2024.

Business

Sanofi eyes €1.3 billion investment in insulin drug plant in Germany

Other healthcare companies such as Daiichi Sankyo have also announced investments in Germany recently, in a positive sign for the ruling coalition government.